Background and Aims: NAFLD is associated with insulin resistance, metabolic syndrome (MS) and diabetes
and it is an independent CVD risk factor. Endothelial Dysfunction (ED) plays a central
role in the pathogenesis of CVD. Preclinical ED can be detected by vascular reactivity
studies, such as Peripheral Arterial Tonometry (PAT). Genome Wide Studies (GWAS) identified
Single Nucleotide Polymorphisms (SNPs) associated to NAFLD progression. Some of them
(ie TM6SF2) have been postulated to influence CVD risk. The use of specific biomarkers
related to ED presence in NAFLD may allow an early identification of CVD risk and
provide crucial insights into its pathophysiology. This could be addressed through
untargeted metabolomics and genomic approaches. Aims: to identify metabolomics signatures
able to discriminate the presence of ED by combining data provided by metabolomics
analyses with those from PAT, and to correlate them with anthropometric, laboratory
and genomic profiles of NAFLD subjects.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Digestive and Liver DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2022 Published by Elsevier Inc.
